Advanced or Metastatic Solid Tumors
72
17
29
21
Key Insights
Highlights
Success Rate
58% trial completion
Published Results
11 trials with published results (15%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
20.8%
15 terminated out of 72 trials
58.3%
-28.2% vs benchmark
0%
0 trials in Phase 3/4
52%
11 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 21 completed trials
Clinical Trials (72)
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies